CATHETER PRECISION INC (VTAK)
US74933X6094 - Common Stock
We assign a fundamental rating of 2 out of 10 to VTAK. VTAK was compared to 187 industry peers in the Health Care Equipment & Supplies industry. VTAK may be in some trouble as it scores bad on both profitability and health. VTAK shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year VTAK has reported negative net income.
VTAK had a negative operating cash flow in the past year.
In the past 5 years VTAK always reported negative net income.
In the past 5 years VTAK always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of VTAK (-36.14%) is worse than 60.22% of its industry peers.
VTAK has a Return On Equity (-66.29%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROIC | N/A |
ROA(3y)-170.3%
ROA(5y)N/A
ROE(3y)-270.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 92.20%, VTAK belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
VTAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTAK has been increased compared to 1 year ago.
Compared to 1 year ago, VTAK has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -16.47, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
VTAK's Altman-Z score of -16.47 is on the low side compared to the rest of the industry. VTAK is outperformed by 86.02% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that VTAK is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.05, VTAK is doing good in the industry, outperforming 61.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.47 |
ROIC/WACCN/A
WACC22.43%
2.3 Liquidity
VTAK has a Current Ratio of 0.12. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK has a Current ratio of 0.12. This is amonst the worse of the industry: VTAK underperforms 97.85% of its industry peers.
VTAK has a Quick Ratio of 0.12. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK's Quick ratio of 0.10 is on the low side compared to the rest of the industry. VTAK is outperformed by 97.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.85% over the past year.
VTAK shows a strong growth in Revenue. In the last year, the Revenue has grown by 134.41%.
The Revenue has been growing by 19.50% on average over the past years. This is quite good.
EPS 1Y (TTM)60.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-384.35%
Revenue 1Y (TTM)134.41%
Revenue growth 3Y19.5%
Revenue growth 5YN/A
Sales Q2Q%-3.12%
3.2 Future
Based on estimates for the next years, VTAK will show a very strong growth in Earnings Per Share. The EPS will grow by 24.76% on average per year.
VTAK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 107.55% yearly.
EPS Next Y27.89%
EPS Next 2Y29.91%
EPS Next 3Y24.76%
EPS Next 5YN/A
Revenue Next Year65.46%
Revenue Next 2Y114.14%
Revenue Next 3Y107.55%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTAK's earnings are expected to grow with 24.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.91%
EPS Next 3Y24.76%
5. Dividend
5.1 Amount
No dividends for VTAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATHETER PRECISION INC
NYSEARCA:VTAK (10/4/2024, 8:04:00 PM)
After market: 0.3601 0 (-0.28%)0.3611
0 (-0.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)60.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y27.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)134.41%
Revenue growth 3Y19.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y